Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy: ABCA/P53/C-myc crosstalk

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J. Clin. 73(1), 17–48 (2023).
   PubMed Web of Science ®Google Scholar
• Novelli F, Milella M, Melucci E et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 10(5), 1–12 (2008).
   Web of Science ®Google Scholar
• Kontoyannis A, Sweetland H. Adjuvant therapy for breast cancer. Surgery (Oxford) 25, 272–275 (2007).
   Google Scholar
• Christowitz C, Davis T, Isaacs A et al. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumor growth in a murine breast tumor model. B.M.C. cancer 19, 1–10 (2019).
   PubMed Web of Science ®Google Scholar
• Yi X, Lou L, Wang J et al. Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway. Cancer Chemother. Pharmacol. 87, 647–656 (2021).
   PubMed Web of Science ®Google Scholar
• Hernandez-Aya LF, Gonzalez-Angulo AM. Adjuvant systemic therapies in breast cancer. Surg. Clin. North Am. 93, 473–491 (2013).
   PubMed Web of Science ®Google Scholar
• Shukla A, Hillegass JM, MacPherson MB et al. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol. Cancer 9, 1–13 (2010).
   PubMed Web of Science ®Google Scholar
• Abrams SL, Steelman LS, Shelton JG et al. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9, 1781–1791 (2010).
   PubMed Web of Science ®Google Scholar
• Yi GY, Kim MJ, Kim HI et al. Hyperthermia treatment as a promising anti-cancer strategy: therapeutic targets, perspective mechanisms and synergistic combinations in experimental approaches. Antioxidants 11, 625 (2022).
   Web of Science ®Google Scholar
• Zhang T, He WH, Feng LL, Huang HG. Effect of doxorubicin-induced ovarian toxicity on mouse ovarian granulosa cells. Regul. Toxicol. Pharmacol. 86, 1–10 (2017).
   PubMed Web of Science ®Google Scholar
• Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Fron. Oncol. 3, 251 (2013).
   PubMedGoogle Scholar
• Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21, 3233 (2020).
   PubMed Web of Science ®Google Scholar
• Ween M, Armstrong M, Oehler M, Ricciardelli C. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit. Rev. Oncol. Hematol. 96, 220–256 (2015).
   PubMed Web of Science ®Google Scholar
• Cerovska E, Elsnerova K, Vaclavikova R, Soucek P. The role of membrane transporters in ovarian cancer chemoresistance and prognosis. Expert Opin. Drug Metab. Toxicol. 13, 741–753 (2017).
   PubMed Web of Science ®Google Scholar
• Wang W, Lokman NA, Noye TM et al. ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome. CDR 4, 485 (2021).
   Google Scholar
• Rizzotto D, Englmaier L, Villunger A. At a crossroads to cancer: how p53-induced cell fate decisions secure genome integrity. Int. J. Mol. Sci. 22, 10883 (2021).
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in context. Cell 170, 1062–1078 (2017).
   PubMed Web of Science ®Google Scholar
• Krause K, Wasner M, Reinhard W et al. The tumor suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res. 28, 4410–4418 (2000).
   PubMed Web of Science ®Google Scholar
• Wang H, Yan C. A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13, 611–IN616 (2011).
   PubMed Web of Science ®Google Scholar
• Shamas-Din A, Kale J, Leber B, Andrews DW. Mechanisms of action of Bcl-2 family proteins. Cold Spring Harb. Perspect. Biol. 5, a008714 (2013).
   PubMed Web of Science ®Google Scholar
• Muller PA, Vousden KH. p53 mutations in cancer. Nat. Cell Biol. 15, 2–8 (2013).
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu N, Liu J et al. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Cell Cycle 18, 3442–3455 (2019).
   PubMed Web of Science ®Google Scholar
• Masui K, Tanaka K, Akhavan D et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 18, 726–739 (2013).
   PubMed Web of Science ®Google Scholar
• Sheth A, Escobar-Alvarez S, Gardner J et al. Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers. Cell Death Dis. 5, e1152 (2014).
   PubMed Web of Science ®Google Scholar
• Gomez-Casares M, Garcia-Alegria E, Lopez-Jorge C et al. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1. Oncogene 32, 2239–2246 (2013).
   PubMed Web of Science ®Google Scholar
• Singh AM, Dalton S. The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell 5, 141–149 (2009).
   PubMed Web of Science ®Google Scholar
• Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21, 3414–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Tsai W-B, Aiba I, Long Y et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells activation of Ras/PI3K/AKT for c-Myc stability by ADI-PEG20. Cancer Res. 72, 2622–2633 (2012).
   PubMedGoogle Scholar
• Pan X-N, Chen J-J, Wang L-X et al. Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation. PLOS ONE 9, e105381 (2014).
   PubMed Web of Science ®Google Scholar
• Bengtsson Y, Sandsveden M, Borgquist S, Manjer J. Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study. Breast Cancer Res. Treat. 189, 571–583 (2021).
   PubMed Web of Science ®Google Scholar
• Chandler P, Kochupurakkal BS, Alam S et al. Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer. Mol. Cancer 15, 1–19 (2016).
   PubMed Web of Science ®Google Scholar
• Jouybari L, Kiani F, Akbari A et al. A meta-analysis of zinc levels in breast cancer. J. Trace. Elem. Med. Biol. 56, 90–99 (2019).
   PubMed Web of Science ®Google Scholar
• Bong AH, Monteith GR. Calcium signaling and the therapeutic targeting of cancer cells. Biochim. Biophys. Acta - Mol. Cell Res. 1865, 1786–1794 (2018).
   PubMed Web of Science ®Google Scholar
• Venturelli S, Leischner C, Helling T et al. Minerals and cancer: overview of the possible diagnostic value. Cancers 14, 1256 (2022).
   PubMed Web of Science ®Google Scholar
• Kawassaki RK, Romano M, Dietrich N, Araki K. Titanium and iron oxide nanoparticles for cancer therapy: surface chemistry and biological implications. Front. Nanotechnol. 3, 735434 (2021).
   Google Scholar
• Kim H, Jeon D, Oh S et al. Titanium dioxide nanoparticles induce apoptosis by interfering with EGFR signaling in human breast cancer cells. Environ. Res. 175, 117–123 (2019).
   PubMed Web of Science ®Google Scholar
• Wang H, Huang Y. Combination therapy based on Nano-delivery for overcoming cancer drug resistance. Med. Drug Discov. 6, 100024 (2020).
   Google Scholar
• Hakkak R, Holley AW, MacLeod SL et al. Obesity promotes 7, 12-dimethylbenz (a) anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res. 7, 1–7 (2005).
   PubMed Web of Science ®Google Scholar
• Gindler EM, King JD. Rapid colorimetric determination of calcium in biologic fluids with methylthymol blue. Am. J. Clin. Pathol. 58, 376–382 (1972).
   PubMed Web of Science ®Google Scholar
• Hayakawa R, Jap J. Chemical method for determination of zinc in serum. Jap. J. Toxic Environ. Health 8, 14–18 (1961).
   Google Scholar
• Abdel-Megeed RM, Abd El-Alim SH, Arafa AF et al. Crosslink among phosphatidylinositol-3 kinase/Akt, PTEN and STAT-5A signaling pathways post liposomal galactomannan hepatocellular carcinoma therapy. Toxicol. Rep. 7, 1531–1541 (2020).
   PubMed Web of Science ®Google Scholar
• Abdel-Megeed RM, El Newary SA, Kadry MO et al. Hyssopus officinalis exerts hypoglycemic effects on streptozotocin-induced diabetic rats via modulating GSK-3β, C-fos, NF-κB, ABCA1 and ABGA1 gene expression. J. Diabetes Metab. Disord. 19, 483–491 (2020).
   PubMed Web of Science ®Google Scholar
• Li B, Zhou P, Xu K et al. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma. Int. J. Biol. Sci. 16, 74 (2020).
   PubMed Web of Science ®Google Scholar
• Alam S, Kelleher SL. Cellular mechanisms of zinc dysregulation: a perspective on zinc homeostasis as an etiological factor in the development and progression of breast cancer. Nutrients 4(8), 875–903 (2012).
   PubMed Web of Science ®Google Scholar
• Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J. Cardiol. 80(2), 125–132 (2022).
   PubMed Web of Science ®Google Scholar
• Tajbakhsh A, Pasdar A, Rezaee M et al. The current status and perspectives regarding the clinical implication of intracellular calcium in breast cancer. J. Cell. Physiol. 233(8), 5623–5641 (2018).
   PubMed Web of Science ®Google Scholar
• González de Vega R, Fernández-Sánchez ML, Pisonero J et al. Quantitative bioimaging of Ca, Fe, Cu and Zn in breast cancer tissues by LA-ICP-MS. J. Anal. At. Spectrom. 32, 671–677 (2017).
   Web of Science ®Google Scholar
• Shang Y, Zhang Z, Liu Z et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene 33, 3267–3276 (2014).
   PubMed Web of Science ®Google Scholar
• Wu K, Zou L, Lei X, Yang X. Roles of ABCA1 in cancer. Oncol. Lett. 24, 1–7 (2022).
   Web of Science ®Google Scholar
• Belisario DC, Akman M, Godel M et al. ABCA1/ABCB1 ratio determines chemo-and immune-sensitivity in human osteosarcoma. Cells 9, 647 (2020).
   PubMed Web of Science ®Google Scholar
• Wang S-M, Lin W-C, Lin H-Y et al. CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma. Cell Death Discov. 7, 8 (2021).
   PubMed Web of Science ®Google Scholar
• Jacobo-Albavera L, Domínguez-Pérez M, Medina-Leyte DJ et al. The role of the ATP-binding cassette A1 (ABCA1) in human disease. Int. J. Mol. Sci. 22, 1593 (2021).
   PubMed Web of Science ®Google Scholar
• Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget 8, 8921 (2017).
   PubMedGoogle Scholar
• Aggarwal M. 2,2-diphenethyl isothiocyanate enhances topoisomerase inhibitor-induced cell death and suppresses multi-drug resistance 1 in breast cancer cells. Cancers 15, 928 (2023).
   PubMed Web of Science ®Google Scholar
• Nishikawa S, Iwakuma T. Drugs targeting p53 mutations with FDA approval and in clinical trials. Cancers 15, 429 (2023).
   PubMed Web of Science ®Google Scholar
• Huang Y, Sadée W. Membrane transporters and channels in chemoresistance and-sensitivity of tumor cells. Cancer Lett. 239, 168–182 (2006).
   PubMed Web of Science ®Google Scholar
• Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochem. Pharmacol. 83, 1136–1145 (2012).
   PubMed Web of Science ®Google Scholar
• Behera R, Kumar V, Lohite K et al. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 31, 192–200 (2010).
   PubMed Web of Science ®Google Scholar
• Schneider J, Jeon YW, Suh YJ, Lim ST. Effects of ruxolitinib and calcitriol combination treatment on various molecular subtypes of breast cancer. Int. J. Mol. Sci. 23, 2535 (2022).
   PubMed Web of Science ®Google Scholar
• Balko JM, Schwarz LJ, Luo N et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci. Transl. Med. 8, 334ra353 (2016).
   Web of Science ®Google Scholar
• Soucek L, Evan GI. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 20, 91–95 (2010).
   PubMed Web of Science ®Google Scholar
• Qu H, Qi D, Wang X et al. CLDN6 suppresses c–MYC–mediated aerobic glycolysis to inhibit proliferation by TAZ in breast cancer. Int. J. Mol. Sci. 23, 129 (2021).
   PubMed Web of Science ®Google Scholar
• Kang JL, Moon C, Lee HS et al. Comparison of the biological activity between ultrafine and fine titanium dioxide particles in RAW 264.7 cells associated with oxidative stress. J. Toxicol. Environ. 71, 478–485 (2008).
   Google Scholar
• Kang SJ, Kim BM, Lee YJ, Chung HW. Titanium dioxide nanoparticles trigger p53-mediated damage response in peripheral blood lymphocytes. Environ. Mol. Mutagen. 49, 399–405 (2008).
   PubMed Web of Science ®Google Scholar
• Petković J, Küzma T, Rade K et al. Pre-irradiation of anatase TiO2 particles with UV enhances their cytotoxic and genotoxic potential in human hepatoma HepG2 cells. J. Hazard. Mater. 196, 145–152 (2011).
   PubMed Web of Science ®Google Scholar
• Tian Y et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35(7), 2383–2390 (2014).
   PubMed Web of Science ®Google Scholar
• Vahabi L, Ranjbar PR, Davar F. Cladosporium protease/doxorubicin decorated Fe3O4@ SiO2 nanocomposite: an efficient nanoparticle for drug delivery and combating breast cancer. J. Drug. Deliv. Sci. Technol. 80, 104144 (2023).
   Web of Science ®Google Scholar